跳至主要内容
临床试验/NCT00205933
NCT00205933已完成不适用

Behavioral Processes Underlying Reward Processing in Depression

Affective Neuroscience Laboratory2 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2004年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
78
试验地点
2

研究概览

简要总结

The purpose of this project is to use behavioral techniques to investigate emotional processing in subjects with major depression and healthy comparison subjects.

详细描述

A promising strategy for parsing the heterogeneity of Major Depressive Disorder is to identify phenotypes characterized by reliable functional abnormalities. Anhedonia, the lack of reactivity to pleasurable stimuli, is considered a trait marker for depression. Using an objective behavioral task this project aims to investigate hedonic capacity in subjects meeting a DSM-IV diagnosis of Major Depressive Disorder.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Depressed participants:
  • Right-handed
  • DSM-IV diagnosis of MDD
  • Score of at least 17 on the 21-item HAM-D scale
  • Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
  • No current or past history of MDD with psychotic features
  • Absence of any other Axis I or Axis II diagnosis (Including bipolar disorder and current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded, since dopaminergic alterations have been reported in these conditions. Exclusion of patients with comorbid Axis I or Axis II diagnoses will be necessary as evidence exists of alteration in dopamine receptor density in detached personality and social phobia. The alteration of dopamine in the brain may in turn alter behavior.
  • Absence of significant medical conditions
  • Absence of ECT in the previous 6 months
  • Ability to provide informed consent/authorization
  • Bipolar participants:
  • Both genders and all ethnic origins
  • Age between 18 and 64
  • Right-handed
  • DSM-IV diagnosis of Bipolar Disorder I or II
  • Score of at least 17 on the 21-item Hamilton Depression Rating Scale (HAM-D)
  • Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
  • No current or past history of MDD with psychotic features
  • Absence of any other Axis I or Axis II diagnosis (Including current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded.
  • Absence of significant medical conditions
  • Absence of ECT in the previous 6 months
  • Ability to provide informed consent/authorization
  • Control Participants:
  • Right-handed
  • Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by the SCID
  • Absence of any medications for at least 2 weeks
  • Informed consent/authorization

排除标准

  • Left-handed/ambidextrous
  • Evidence of neurological illness
  • Current alcohol or substance abuse
  • Serious suicide or homicide risk

研究者

发起方
Affective Neuroscience Laboratory
申办方类型
Other

研究点 (2)

Loading locations...

相似试验